Vera Therapeutics, Inc. (NASDAQ:VERA) Position Raised by Cutter Capital Management LP

Cutter Capital Management LP lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 23.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 212,696 shares of the company's stock after acquiring an additional 39,820 shares during the period. Vera Therapeutics accounts for 3.7% of Cutter Capital Management LP's portfolio, making the stock its 13th biggest holding. Cutter Capital Management LP owned about 0.34% of Vera Therapeutics worth $8,995,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Huntington National Bank bought a new position in Vera Therapeutics in the 4th quarter worth approximately $26,000. Summit Investment Advisors Inc. raised its stake in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares in the last quarter. AlphaQuest LLC acquired a new stake in Vera Therapeutics in the fourth quarter worth about $34,000. Alliancebernstein L.P. grew its position in Vera Therapeutics by 2.0% in the 4th quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock valued at $1,706,000 after buying an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after buying an additional 1,130 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on VERA. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective on the stock. HC Wainwright initiated coverage on shares of Vera Therapeutics in a research report on Monday. They issued a "buy" rating and a $75.00 price target on the stock. Wolfe Research started coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. Guggenheim lifted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Vera Therapeutics currently has an average rating of "Buy" and a consensus target price of $65.70.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $25.53 on Tuesday. The firm has a fifty day moving average price of $24.78 and a two-hundred day moving average price of $35.16. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The company has a market cap of $1.63 billion, a PE ratio of -9.78 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. Analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.